-
The Investigational Oral Anti-Cancer Drug CVM-1118 Receives NMPA Approval to Initiate a Phase II Clinical Trial for Intermediate-Stage Liver Cancer in China.
The anti-cancer drug, CVM-1118, has received approval f…
-
TaiRx’s New Drug CVM-1118 Granted Orphan Drug Designation for Pancreatic Neuroendocrine Tumors (PNETs), Securing Seven Years of Market Exclusivity in the U.S.
TaiRx’s orally administered anticancer drug, CVM-1118 (…
-
Company Announcement for Zelnite®
TaiRx, Inc. hereby declares that Zelnite® is the only s…

